Michel D Ferrari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2246863/publications.pdf

Version: 2024-02-01

500 papers 41,552 citations

94 h-index 183 g-index

511 all docs

511 docs citations

511 times ranked

24714 citing authors

#	Article	IF	CITATIONS
1	Repeated greater occipital nerve injections with corticosteroids in medically intractable chronic cluster headache: a retrospective study. Neurological Sciences, 2022, 43, 1267-1272.	1.9	5
2	Migraine. Nature Reviews Disease Primers, 2022, 8, 2.	30.5	154
3	Elucidating the relationship between migraine risk and brain structure using genetic data. Brain, 2022, 145, 3214-3224.	7.6	7
4	Unilateral increased visual sensitivity in cluster headache: a cross-sectional study. Cephalalgia, 2022, , 033310242210776.	3.9	1
5	CaV2.1 channel mutations causing familial hemiplegic migraine type 1 increase the susceptibility for cortical spreading depolarizations and seizures and worsen outcome after experimental traumatic brain injury. ELife, 2022, 11 , .	6.0	5
6	Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache, 2022, 62, 530-533.	3.9	2
7	Rapid Prototyping of Organ-on-a-Chip Devices Using Maskless Photolithography. Micromachines, 2022, 13, 49.	2.9	11
8	COVID-19 vaccination-triggered cluster headache episodes with frequent attacks. Cephalalgia, 2022, 42, 1420-1424.	3.9	7
9	Responsivity to light in familial hemiplegic migraine type 1 mutant mice reveals frequencyâ€dependent enhancement of visual network excitability. European Journal of Neuroscience, 2021, 53, 1672-1686.	2.6	8
10	Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 466-472.	1.9	13
11	Long-term Efficacy and Safety of Erenumab. Neurology, 2021, 96, .	1.1	25
12	Time lost due to an attack – a novel patient-reported outcome measure for acute migraine treatments. Cephalalgia, 2021, 41, 1027-1032.	3.9	3
13	Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception) Tj ETQq $1\ 1\ 0.784$	4314 rgBT 3.3	/Overlock 10
14	Hypothalamic functional MRI activity in the initiation phase of spontaneous and glyceryl trinitrateâ€nduced migraine attacks. European Journal of Neuroscience, 2021, 54, 5189-5202.	2.6	9
15	Headache in people with epilepsy. Nature Reviews Neurology, 2021, 17, 529-544.	10.1	21
16	Genetic Susceptibility Loci in Genomewide Association Study of Cluster Headache. Annals of Neurology, 2021, 90, 203-216.	5.3	22
17	Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurology, The, 2021, 20, 515-525.	10.2	28
18	The effect of needle size on cerebrospinal fluid collection time and postâ€dural puncture headache: A retrospective cohort study. Headache, 2021, 61, 329-334.	3.9	5

#	Article	IF	Citations
19	Sex Differences in Risk Profile, Stroke Cause and Outcome in Ischemic Stroke Patients With and Without Migraine. Frontiers in Neuroscience, 2021, 15, 740639.	2.8	4
20	Cortical glutamate and gamma-aminobutyric acid over the course of a provoked migraine attack, a 7 Tesla magnetic resonance spectroscopy study. Neurolmage: Clinical, 2021, 32, 102889.	2.7	7
21	MRI evaluation of the relationship between carotid artery endothelial shear stress and brain white matter lesions in migraine. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1040-1047.	4.3	14
22	The cardiovascular risk profile of middleâ€aged women with polycystic ovary syndrome. Clinical Endocrinology, 2020, 92, 150-158.	2.4	36
23	Abnormal cardiovascular response to nitroglycerin in migraine. Cephalalgia, 2020, 40, 266-277.	3.9	2
24	Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine. Brain, 2020, 143, e6-e6.	7.6	2
25	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	3.9	105
26	NOn-invasive Vagus nerve stimulation in acute Ischemic Stroke (NOVIS): a study protocol for a randomized clinical trial. Trials, 2020, 21, 878.	1.6	11
27	Premonitory symptoms in glyceryl trinitrate triggered migraine attacks: a case-control study. Pain, 2020, 161, 2058-2067.	4.2	17
28	Habitual sleep disturbances and migraine: a Mendelian randomization study. Annals of Clinical and Translational Neurology, 2020, 7, 2370-2380.	3.7	18
29	Enhanced pre-ictal cortical responsivity in migraine patients assessed by visual chirp stimulation. Cephalalgia, 2020, 40, 913-923.	3.9	6
30	A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine. Nature Communications, 2020, 11 , 3368.	12.8	49
31	Antiâ€migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. Annals of Neurology, 2020, 88, 771-784.	5.3	64
32	Pharmacotherapy for Cluster Headache. CNS Drugs, 2020, 34, 171-184.	5.9	35
33	Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. International Journal of Epidemiology, 2020, 49, 1022-1031.	1.9	34
34	European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020, 58, 1-464.	1.3	1,555
35	Linking migraine frequency with family history of migraine. Cephalalgia, 2019, 39, 229-236.	3.9	30
36	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet, The, 2019, 394, 1030-1040.	13.7	269

#	Article	IF	Citations
37	Relief Following Chronic Stress Augments Spreading Depolarization Susceptibility in Familial Hemiplegic Migraine Mice. Neuroscience, 2019, 415, 1-9.	2.3	12
38	AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nature Communications, 2019, 10, 3094.	12.8	150
39	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia, 2019, 39, 1475-1487.	3.9	69
40	Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination. Brain, 2019, 142, 2948-2964.	7.6	43
41	Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. Cephalalgia, 2019, 39, 967-977.	3.9	35
42	Treatment effects and comorbid diseases in 58 patients with visual snow. Neurology, 2019, 93, e398-e403.	1.1	49
43	Stroke progression and clinical outcome in ischemic stroke patients with a history of migraine. International Journal of Stroke, 2019, 14, 946-955.	5.9	9
44	The biological clock in cluster headache: A review and hypothesis. Cephalalgia, 2019, 39, 1855-1866.	3.9	29
45	Chronobiology and Sleep in Cluster Headache. Headache, 2019, 59, 1032-1041.	3.9	19
46	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia, 2019, 39, 1058-1066.	3.9	4
47	Coronary artery calcification in middleâ€aged women with premature ovarian insufficiency. Clinical Endocrinology, 2019, 91, 314-322.	2.4	18
48	Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain, 2019, 142, 1203-1214.	7.6	68
49	Phase clustering in transcranial magnetic stimulation-evoked EEG responses in genetic generalized epilepsy and migraine. Epilepsy and Behavior, 2019, 93, 102-112.	1.7	9
50	Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine. Neurology, 2019, 92, e1899-e1911.	1.1	42
51	Circle of Willis variations in migraine patients with ischemic stroke. Brain and Behavior, 2019, 9, e01223.	2.2	6
52	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	3.9	154
53	096â€Assessment of the efficacy of erenumab during the open-label treatment (13–24 weeks) of subjects with episodic migraine who failed 2–4 prior preventive treatments: results of the LIBERTY study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A31.1-A31.	1.9	0
54	Microstructural white matter changes preceding white matter hyperintensities in migraine. Neurology, 2019, 93, e688-e694.	1.1	15

#	Article	IF	CITATIONS
55	Migraine polygenic risk score associates with efficacy of migraine-specific drugs. Neurology: Genetics, 2019, 5, e364.	1.9	28
56	Reply. Pain, 2019, 160, 985-985.	4.2	0
57	Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine. European Journal of Neurology, 2019, 26, 588-595.	3.3	29
58	Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. Journal of Internal Medicine, 2019, 285, 317-332.	6.0	29
59	Brainstem spreading depolarization and cortical dynamics during fatal seizures in <i>Cacnala</i> S218L mice. Brain, 2019, 142, 412-425.	7.6	79
60	Cardiovascular risk prediction models for women in the general population: A systematic review. PLoS ONE, 2019, 14, e0210329.	2.5	35
61	Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy. Heart, 2019, 105, 330-336.	2.9	8
62	Increased use of illicit drugs in a Dutch cluster headache population. Cephalalgia, 2019, 39, 626-634.	3.9	21
63	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	3.9	245
64	Clinical spectrum of hemiplegic migraine and chances of finding a pathogenic mutation. Neurology, 2018, 90, e575-e582.	1.1	59
65	Primary headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 267-284.	1.8	2
66	Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families. Neuron, 2018, 98, 743-753.e4.	8.1	63
67	Strategies to assess and optimize stability of endogenous amines during cerebrospinal fluid sampling. Metabolomics, 2018, 14, 44.	3.0	7
68	Migraine and vascular disease biomarkers: A population-based case-control study. Cephalalgia, 2018, 38, 511-518.	3.9	36
69	Chronotypes and circadian timing in migraine. Cephalalgia, 2018, 38, 617-625.	3.9	60
70	Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia, 2018, 38, 959-969.	3.9	153
71	Brain atrophy following hemiplegic migraine attacks. Cephalalgia, 2018, 38, 1199-1202.	3.9	19
72	Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 434-435.	1.9	10

#	Article	IF	CITATIONS
73	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet, The, 2018, 392, 2280-2287.	13.7	348
74	Quantifying visual allodynia across migraine subtypes: the Leiden Visual Sensitivity Scale. Pain, 2018, 159, 2375-2382.	4.2	41
75	Female sex hormones in men with migraine. Neurology, 2018, 91, e374-e381.	1.1	44
76	Aura in Cluster Headache: A Crossâ€Sectional Study. Headache, 2018, 58, 1203-1210.	3.9	14
77	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
78	RVCL-S and CADASIL display distinct impaired vascular function. Neurology, 2018, 91, e956-e963.	1.1	23
79	Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia, 2017, 37, 49-63.	3.9	109
80	Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1595-1625.	4.3	255
81	Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel <i>ATP1A2</i> mutation. Cephalalgia, 2017, 37, 737-755.	3.9	28
82	Optogenetic induction of cortical spreading depression in anesthetized and freely behaving mice. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1641-1655.	4.3	66
83	Cortical Spreading Depression Causes Unique Dysregulation of Inflammatory Pathways in a Transgenic Mouse Model of Migraine. Molecular Neurobiology, 2017, 54, 2986-2996.	4.0	37
84	The cavernous sinus in cluster headache – a quantitative structural magnetic resonance imaging study. Cephalalgia, 2017, 37, 208-213.	3.9	5
85	Cerebellar function and ischemic brain lesions in migraine patients from the general population. Cephalalgia, 2017, 37, 177-190.	3.9	22
86	Identifying a gene expression signature of cluster headache in blood. Scientific Reports, 2017, 7, 40218.	3.3	20
87	Inhibition of the P2X7–PANX1 complex suppresses spreading depolarization and neuroinflammation. Brain, 2017, 140, 1643-1656.	7.6	99
88	Allodynia in cluster headache. Pain, 2017, 158, 1113-1117.	4.2	22
89	Cortical glutamate in migraine. Brain, 2017, 140, 1859-1871.	7.6	81
90	Migraine and Cerebrovascular Atherosclerosis in Patients With Ischemic Stroke. Stroke, 2017, 48, 1973-1975.	2.0	33

#	Article	lF	Citations
91	Iron in deep brain nuclei in migraine? CAMERA follow-up MRI findings. Cephalalgia, 2017, 37, 795-800.	3.9	15
92	Valproate Reduces Delayed Brain Injury in a Rat Model of Subarachnoid Hemorrhage. Stroke, 2017, 48, 452-458.	2.0	15
93	Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. Journal of Lipid Research, 2017, 58, 615-624.	4.2	33
94	Volumetric brain changes in migraineurs from the general population. Neurology, 2017, 89, 2066-2074.	1.1	44
95	Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. Stroke, 2017, 48, 3301-3307.	2.0	13
96	The anterior hypothalamus in cluster headache. Cephalalgia, 2017, 37, 1039-1050.	3.9	50
97	Slowing Down of Recovery as Generic Risk Marker for Acute Severity Transitions in Chronic Diseases. Critical Care Medicine, 2016, 44, 601-606.	0.9	73
98	Cardiac monitoring of high-dose verapamil in cluster headache: An international Delphi study. Cephalalgia, 2016, 36, 1385-1388.	3.9	14
99	Spreading depolarizations increase delayed brain injury in a rat model of subarachnoid hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1224-1231.	4.3	30
100	Spreading depolarization-modulating drugs and delayed cerebral ischemia after subarachnoid hemorrhage: A hypothesis-generating retrospective clinical study. Journal of the Neurological Sciences, 2016, 366, 224-228.	0.6	1
101	Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain, 2016, 139, 2909-2922.	7.6	114
102	Cluster headache and depression. Neurology, 2016, 87, 1899-1906.	1.1	47
103	Role of atherosclerosis, clot extent, and penumbra volume in headache during ischemic stroke. Neurology, 2016, 87, 1124-1130.	1.1	12
104	Metabolomic changes in CSF of migraine patients measured with $\langle \sup 1 \langle \sup H-NMR $ spectroscopy. Molecular BioSystems, 2016, 12, 3674-3682.	2.9	10
105	Prevalence of lifetime depression in a large hemiplegic migraine cohort. Neurology, 2016, 87, 2370-2374.	1.1	15
106	Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics, 2016, 48, 856-866.	21.4	520
107	Wiping Out CGRP: Potential Cardiovascular Risks. Trends in Pharmacological Sciences, 2016, 37, 779-788.	8.7	179
108	Restless legs syndrome in migraine patients: prevalence and severity. European Journal of Neurology, 2016, 23, 1110-1116.	3.3	25

#	Article	IF	CITATIONS
109	Gene-based pleiotropy across migraine with aura and migraine without aura patient groups. Cephalalgia, 2016, 36, 648-657.	3.9	47
110	Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia, 2016, 36, 148-161.	3.9	88
111	Involvement of astrocyte and oligodendrocyte gene sets in migraine. Cephalalgia, 2016, 36, 640-647.	3.9	15
112	Systemic right-to-left shunts, ischemic brain lesions, and persistent migraine activity. Neurology, 2016, 86, 1668-1675.	1.1	16
113	Gene co-expression analysis identifies brain regions and cell types involved in migraine pathophysiology: a GWAS-based study using the Allen Human Brain Atlas. Human Genetics, 2016, 135, 425-439.	3.8	47
114	An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP). Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 790-791.	1.9	10
115	Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?. Cephalalgia, 2016, 36, 122-130.	3.9	36
116	Evaluation of the new ICHD-III beta cluster headache criteria. Cephalalgia, 2016, 36, 547-551.	3.9	21
117	Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia, 2016, 36, 604-614.	3.9	41
118	Infratentorial Microbleeds. Stroke, 2015, 46, 1987-1989.	2.0	13
119	European headache federation consensus on technical investigation for primary headache disorders. Journal of Headache and Pain, 2015, 17, 5.	6.0	97
120	Cluster headache and the hypocretin receptor 2 reconsidered: A genetic association study and meta-analysis. Cephalalgia, 2015, 35, 741-747.	3.9	50
121	Abnormal synaptic <scp>C</scp> a ²⁺ homeostasis and morphology in cortical neurons of familial hemiplegic migraine type 1 mutant mice. Annals of Neurology, 2015, 78, 193-210.	5.3	39
122	Concordance of genetic risk across migraine subgroups: Impact on current and future genetic association studies. Cephalalgia, 2015, 35, 489-499.	3.9	32
123	Ethanol contamination of cerebrospinal fluid during standardized sampling and its effect on 1H-NMR metabolomics. Analytical and Bioanalytical Chemistry, 2015, 407, 4835-4839.	3.7	12
124	Shared genetic basis for migraine and ischemic stroke. Neurology, 2015, 84, 2132-2145.	1.1	91
125	Understanding migraine using dynamic network biomarkers. Cephalalgia, 2015, 35, 627-630.	3.9	27
126	Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia, 2015, 35, 500-507.	3.9	20

#	Article	IF	Citations
127	Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. Journal of Affective Disorders, 2015, 172, 453-461.	4.1	15
128	Familial hemiplegic migraine type-1 mutated cav2.1 calcium channels alter inhibitory and excitatory synaptic transmission in the lateral superior olive of mice. Hearing Research, 2015, 319, 56-68.	2.0	6
129	The comorbid relationship between migraine and epilepsy: a systematic review and metaâ€analysis. European Journal of Neurology, 2015, 22, 1038-1047.	3.3	35
130	Migraine Mutations Impair Hippocampal Learning Despite Enhanced Long-Term Potentiation. Journal of Neuroscience, 2015, 35, 3397-3402.	3.6	34
131	Reduced trigeminovascular cyclicity in patients with menstrually related migraine. Neurology, 2015, 84, 125-131.	1.1	39
132	A human capsaicin model to quantitatively assess salivary CGRP secretion. Cephalalgia, 2015, 35, 675-682.	3.9	11
133	Space headache on Earth: Head-down-tilted bed rest studies simulating outer-space microgravity. Cephalalgia, 2015, 35, 335-343.	3.9	15
134	Large-Scale Mass Spectrometry Imaging Investigation of Consequences of Cortical Spreading Depression in a Transgenic Mouse Model of Migraine. Journal of the American Society for Mass Spectrometry, 2015, 26, 853-861.	2.8	27
135	From migraine genes to mechanisms. Pain, 2015, 156, S64-S74.	4.2	63
136	Plasma metabolic profiling after cortical spreading depression in a transgenic mouse model of hemiplegic migraine by capillary electrophoresis – mass spectrometry. Molecular BioSystems, 2015, 11, 1462-1471.	2.9	37
137	Genetic analysis for a shared biological basis between migraine and coronary artery disease. Neurology: Genetics, 2015, 1, e10.	1.9	61
138	Symptom dimensions of affective disorders in migraine patients. Journal of Psychosomatic Research, 2015, 79, 458-463.	2.6	33
139	Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurology, The, 2015, 14, 65-80.	10.2	313
140	A novel <i>SLC2A1</i> mutation linking hemiplegic migraine with alternating hemiplegia of childhood. Cephalalgia, 2015, 35, 10-15.	3.9	28
141	Migraine Prophylaxis, Ischemic Depolarizations, and Stroke Outcomes in Mice. Stroke, 2015, 46, 229-236.	2.0	38
142	Stress hormone corticosterone enhances susceptibility to cortical spreading depression in familial hemiplegic migraine type 1 mutant mice. Experimental Neurology, 2015, 263, 214-220.	4.1	27
143	Microfabricated solid-state ion-selective electrode probe for measuring potassium in the living rodent brain: Compatibility with DC-EEG recordings to study spreading depression. Sensors and Actuators B: Chemical, 2015, 207, 945-953.	7.8	23
144	Migraine with Aura: A CADASIL Case. Headache, 2015, , 53-58.	0.4	0

#	Article	IF	Citations
145	What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study. PLoS ONE, 2014, 9, e98933.	2.5	48
146	Synaptic Gain-of-Function Effects of Mutant Ca _v 2.1 Channels in a Mouse Model of Familial Hemiplegic Migraine Are Due to Increased Basal [Ca ²⁺] _i . Journal of Neuroscience, 2014, 34, 7047-7058.	3.6	45
147	Biochemical changes in the brain of hemiplegic migraine patients measured with 7 tesla ¹ H-MRS. Cephalalgia, 2014, 34, 959-967.	3.9	24
148	EHMTI-0262. Dysregulation of inflammatory pathways in a familial hemiplegic migraine 1 mouse model after the induction of cortical spreading depression. Journal of Headache and Pain, 2014, 15, .	6.0	0
149	<i>PRRT2</i> and hemiplegic migraine: A complex association. Neurology, 2014, 83, 288-290.	1.1	37
150	RNA expression profiling in brains of familial hemiplegic migraine type 1 knock-in mice. Cephalalgia, 2014, 34, 174-182.	3.9	9
151	Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: A Fos protein study. Neurobiology of Disease, 2014, 64, 1-7.	4.4	21
152	Two novel <i>SCN1A</i> mutations identified in families with familial hemiplegic migraine. Cephalalgia, 2014, 34, 1062-1069.	3.9	26
153	What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia, 2014, 34, 29-36.	3.9	86
154	Familial hemiplegic migraine treated by sodium valproate and lamotrigine. Cephalalgia, 2014, 34, 708-711.	3.9	22
155	Allodynia is associated with a higher prevalence of depression in migraine patients. Cephalalgia, 2014, 34, 1187-1192.	3.9	32
156	A hyperexcitability phenotype in mouse trigeminal sensory neurons expressing the R192Q Cacna1a missense mutation of familial hemiplegic migraine type-1. Neuroscience, 2014, 266, 244-254.	2.3	23
157	Epigenetic mechanisms in migraine: a promising avenue?. BMC Medicine, 2013, 11, 26.	5.5	86
158	Familial and Sporadic Hemiplegic Migraine: Diagnosis and Treatment. Current Treatment Options in Neurology, 2013, 15, 13-27.	1.8	72
159	Heterozygous TREX1 mutations in early-onset cerebrovascular disease. Journal of Neurology, 2013, 260, 2188-2190.	3.6	12
160	Migraine without aura: genome-wide association analysis identifies several novel susceptibility. Journal of Headache and Pain, 2013, 14, .	6.0	0
161	Novel SCN1A mutation in the IFMT motif of the $\hat{l}\pm 1$ subunit of the voltage-gated NaV1.1 channel causing familial hemiplegic migraine. Journal of Headache and Pain, 2013, 14, .	6.0	1
162	Migraine without aura: genome-wide association analysis identifies several novel susceptibility. Journal of Headache and Pain, 2013, 14, .	6.0	0

#	Article	IF	Citations
163	Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study. Journal of Headache and Pain, 2013, 14, .	6.0	O
164	Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies. Journal of Headache and Pain, 2013, 14, .	6.0	1
165	Postural sway in migraine patients and controls, results from a population based CAMERA-2 study. Journal of Headache and Pain, 2013, 14, .	6.0	0
166	Corticosterone enhances CSD susceptibility via glucocorticoid receptor activation in familial hemiplegic migraine 1 Cacna1a knock-in mice. Journal of Headache and Pain, 2013, 14, .	6.0	0
167	Monitoring cortical neuronal activity and spreading depression in freely behaving familial hemiplegic migraine Cacna1a R192Q knockin mice. Journal of Headache and Pain, 2013, 14, .	6.0	0
168	Preventive treatment for migraine in primary care, a population-based study in the Netherlands. Cephalalgia, 2013, 33, 1170-1178.	3.9	20
169	Behavioral evidence for photophobia and stress-related ipsilateral head pain in transgenic Cacnala mutant mice. Pain, 2013, 154, 1254-1262.	4.2	76
170	Headache: the changing migraine brain. Lancet Neurology, The, 2013, 12, 6-8.	10.2	10
171	Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nature Genetics, 2013, 45, 912-917.	21.4	338
172	Pearls and pitfalls in genetic studies of migraine. Cephalalgia, 2013, 33, 614-625.	3.9	38
173	Cutaneous allodynia as a predictor of migraine chronification. Brain, 2013, 136, 3489-3496.	7.6	202
174	Concomitant Headache Influences Long-term Prognosis After Acute Cerebral Ischemia of Noncardioembolic Origin. Stroke, 2013, 44, 2446-2450.	2.0	9
175	Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls. Neurology, 2013, 80, 1958-1965.	1.1	45
176	Postdural puncture headache in migraineurs and nonheadache subjects. Neurology, 2013, 80, 941-948.	1.1	39
177	Occipital nerve stimulation in medically intractable, chronic cluster headache. The ICON study: Rationale and protocol of a randomised trial. Cephalalgia, 2013, 33, 1238-1247.	3.9	73
178	Clusterâ€Tic Syndrome: A Crossâ€Sectional Study of Cluster Headache Patients. Headache, 2013, 53, 1334-1340.	3.9	16
179	Migraine is not associated with enhanced atherosclerosis. Cephalalgia, 2013, 33, 228-235.	3.9	57
180	Stepwise web-based questionnaires for diagnosing cluster headache: LUCA and QATCH. Cephalalgia, 2013, 33, 924-931.	3.9	25

#	Article	IF	CITATIONS
181	Reduced Sleep and Low Adenosinergic Sensitivity in Cacnala R192Q Mutant Mice. Sleep, 2013, 36, 127-136.	1.1	32
182	Migraine Strikes as Neuronal Excitability Reaches a Tipping Point. PLoS ONE, 2013, 8, e72514.	2.5	22
183	TNFα Levels and Macrophages Expression Reflect an Inflammatory Potential of Trigeminal Ganglia in a Mouse Model of Familial Hemiplegic Migraine. PLoS ONE, 2013, 8, e52394.	2.5	74
184	The Mechanism of Functional Up-Regulation of P2X3 Receptors of Trigeminal Sensory Neurons in a Genetic Mouse Model of Familial Hemiplegic Migraine Type 1 (FHM-1). PLoS ONE, 2013, 8, e60677.	2.5	31
185	Cerebellar Ataxia by Enhanced Ca _V 2.1 Currents Is Alleviated by Ca ²⁺ -Dependent K ⁺ -Channel Activators in <i>Cacnala</i> ^{S218L} Mutant Mice. Journal of Neuroscience, 2012, 32, 15533-15546.	3.6	84
186	7â€~T MRI reveals diffuse iron deposition in putamen and caudate nucleus in CADASIL. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1180-1185.	1.9	43
187	Cerebral perfusion changes in migraineurs: a voxelwise comparison of interictal dynamic susceptibility contrast MRI measurements. Cephalalgia, 2012, 32, 279-288.	3.9	26
188	A proactive approach to migraine in primary care: a pragmatic randomized controlled trial. Cmaj, 2012, 184, E224-E231.	2.0	15
189	Prophylactic treatment of migraine by GPs: a qualitative study. British Journal of General Practice, 2012, 62, e268-e274.	1.4	13
190	Migraine Mutations Increase Stroke Vulnerability by Facilitating Ischemic Depolarizations. Circulation, 2012, 125, 335-345.	1.6	148
191	Aortic root pathology in Marfan syndrome increases the risk of migraine with aura. Cephalalgia, 2012, 32, 467-472.	3.9	10
192	Right-to-left shunts and micro-embolization in migraine. Current Opinion in Neurology, 2012, 25, 263-268.	3.6	1
193	Structural Brain Changes in Migraine. JAMA - Journal of the American Medical Association, 2012, 308, 1889.	7.4	197
194	Imaging mass spectrometry to visualize biomolecule distributions in mouse brain tissue following hemispheric cortical spreading depression. Journal of Proteomics, 2012, 75, 5027-5035.	2.4	35
195	Prophylactic treatment of migraine; the patient's view, a qualitative study. BMC Family Practice, 2012, 13, 13.	2.9	21
196	The adverse effects of antiepileptic drugs differ in patients with migraine. Lancet Neurology, The, 2012, 11, 935.	10.2	4
197	De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nature Genetics, 2012, 44, 1030-1034.	21.4	345
198	Metabolic profiling of mouse cerebrospinal fluid by sheathless CE-MS. Analytical and Bioanalytical Chemistry, 2012, 404, 2895-2900.	3.7	44

#	Article	IF	CITATIONS
199	Presynaptic Ca _V 2.1 calcium channels carrying familial hemiplegic migraine mutation R192Q allow faster recovery from synaptic depression in mouse calyx of Held. Journal of Neurophysiology, 2012, 108, 2967-2976.	1.8	21
200	Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nature Genetics, 2012, 44, 777-782.	21.4	294
201	Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study. Neurological Sciences, 2012, 33, 61-64.	1.9	5
202	Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. Neurological Sciences, 2012, 33, 65-69.	1.9	17
203	Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. Journal of Headache and Pain, 2012, 13, 401-406.	6.0	31
204	Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nature Genetics, 2011, 43, 695-698.	21.4	355
205	Antimigraine Efficacy of Telcagepant Based on Patient's Historical Triptan Response. Headache, 2011, 51, 64-72.	3.9	38
206	Serotonin, NO, and CGRP and Headache. Headache, 2011, 51, 1046-1048.	3.9	1
207	Meta-analysis of genome-wide association for migraine in six population-based European cohorts. European Journal of Human Genetics, 2011, 19, 901-907.	2.8	87
208	A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. Journal of Headache and Pain, 2011, 12, 219-226.	6.0	37
209	A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. Journal of Headache and Pain, 2011, 12, 361-368.	6.0	47
210	Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. Journal of Headache and Pain, 2011, 12, 609-615.	6.0	34
211	Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. Cephalalgia, 2011, 31, 1368-1380.	3.9	30
212	The impact of a migraine attack and its after-effects on perceptual organization, attention, and working memory. Cephalalgia, 2011, 31, 1419-1427.	3.9	31
213	Picasso's migraine: Illusory cubist splitting or illusion?. Cephalalgia, 2011, 31, 1057-1060.	3.9	8
214	Enhanced Subcortical Spreading Depression in Familial Hemiplegic Migraine Type 1 Mutant Mice. Journal of Neuroscience, 2011, 31, 5755-5763.	3.6	119
215	Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs. Cephalalgia, 2011, 31, 1359-1367.	3.9	57
216	A long-term follow-up study of 18 patients with sporadic hemiplegic migraine. Cephalalgia, 2011, 31, 199-205.	3.9	16

#	Article	IF	Citations
217	Functional changes of vascular responses in familial hemiplegic migraine type 1. FASEB Journal, 2011, 25, .	0.5	0
218	Lenticulostriate Arterial Lumina Are Normal in Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke, 2010, 41, 2812-2816.	2.0	30
219	Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurological Sciences, 2010, 31, 51-54.	1.9	34
220	Familial Hemiplegic Migraine Ca _V 2.1 Channel Mutation R192Q Enhances ATP-gated P2X ₃ Receptor Activity of Mouse Sensory Ganglion Neurons Mediating Trigeminal Pain. Molecular Pain, 2010, 6, 1744-8069-6-48.	2.1	59
221	High cortical spreading depression susceptibility and migraineâ€associated symptoms in Ca _v 2.1 S218L mice. Annals of Neurology, 2010, 67, 85-98.	5.3	206
222	Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome. European Journal of Pain, 2010, 14, 523-528.	2.8	54
223	Quantitative cortical synapse proteomics of a transgenic migraine mouse model with mutated Ca _V 2.1 calcium channels. Proteomics, 2010, 10, 2531-2535.	2.2	21
224	Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study. Cephalalgia, 2010, 30, 129-136.	3.9	306
225	Anatomical Variations in the Circle of Willis and Migraine Susceptibility: Is There an Association?. Headache, 2010, 50, 151-152.	3.9	5
226	Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nature Genetics, 2010, 42, 869-873.	21.4	332
227	Coding of facial expressions of pain in the laboratory mouse. Nature Methods, 2010, 7, 447-449.	19.0	1,024
228	Genetics of headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 85-97.	1.8	22
229	Severe and Progressive Neurotransmitter Release Aberrations in Familial Hemiplegic Migraine Type 1 <i>Cacna1a</i> S218L Knock-in Mice. Journal of Neurophysiology, 2010, 104, 1445-1455.	1.8	24
230	CADASIL and migraine: A narrative review. Cephalalgia, 2010, 30, 1284-1289.	3.9	58
231	An early 18th-century case description of cluster headache. Cephalalgia, 2010, 30, 1392-1395.	3.9	4
232	Shared genetic factors in migraine and depression. Neurology, 2010, 74, 288-294.	1.1	90
233	Gain of Function in FHM-1 Cav2.1 Knock-In Mice Is Related to the Shape of the Action Potential. Journal of Neurophysiology, 2010, 104, 291-299.	1.8	33
234	Acute treatment of migraine with the selective 5-HT _{1F} receptor agonist lasmiditan – A randomised proof-of-concept trial. Cephalalgia, 2010, 30, 1170-1178.	3.9	152

#	Article	IF	CITATIONS
235	Metabolic Profiling of Ultrasmall Sample Volumes with GC/MS: From Microliter to Nanoliter Samples. Analytical Chemistry, 2010, 82, 156-162.	6.5	48
236	TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2010, 69, 1886-1887.	0.9	43
237	MRI correlates of cognitive decline in CADASIL. Neurology, 2009, 72, 143-148.	1.1	92
238	Cerebrovascular Reactivity Is a Main Determinant of White Matter Hyperintensity Progression in CADASIL. American Journal of Neuroradiology, 2009, 30, 1244-1247.	2.4	46
239	Episodic Ataxia Associated With EAAT1 Mutation C186S Affecting Glutamate Reuptake. Archives of Neurology, 2009, 66, 97-101.	4. 5	122
240	Reply to: Migraine headache is not associated with cerebral or meningeal vasodilatation—a 3T magnetic resonance angiography study. Brain, 2009, 132, e113-e113.	7.6	3
241	Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Annals of Neurology, 2009, 66, 564-568.	5.3	99
242	Molecular genetics of migraine. Human Genetics, 2009, 126, 115-132.	3.8	255
243	Are Migraineurs at Increased Risk of Adverse Drug Responses?: A Meta-Analytic Comparison of Topiramate-Related Adverse Drug Reactions in Epilepsy and Migraine. Clinical Pharmacology and Therapeutics, 2009, 85, 283-288.	4.7	71
244	Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science. Headache, 2009, 49, S21-33.	3.9	47
245	Familial hemiplegic migraine is associated with febrile seizures in an FHM2 family with a novel de novo <i>ATP1A2</i> mutation. Epilepsia, 2009, 50, 2503-2504.	5.1	26
246	First Mutation in the Voltage-Gated Na _v 1.1 Subunit Gene <i>SCN1A</i> with Co-Occurring Familial Hemiplegic Migraine and Epilepsy. Cephalalgia, 2009, 29, 308-313.	3.9	77
247	Iron Accumulation in Deep Brain Nuclei in Migraine: A Population-Based Magnetic Resonance Imaging Study. Cephalalgia, 2009, 29, 351-359.	3.9	132
248	Space Headache: A New Secondary Headache. Cephalalgia, 2009, 29, 683-686.	3.9	28
249	Migraine and Genetic and Acquired Vasculopathies. Cephalalgia, 2009, 29, 1006-1017.	3.9	61
250	No indication for patent foramen ovale closure in migraine. Netherlands Heart Journal, 2009, 17, 320-321.	0.8	4
251	Enhanced Excitatory Transmission at Cortical Synapses as the Basis for Facilitated Spreading Depression in CaV2.1 Knockin Migraine Mice. Neuron, 2009, 61, 762-773.	8.1	292
252	IN64-FR-01 From migraine genes to migraine triggering mechanisms and prophylaxis. Journal of the Neurological Sciences, 2009, 285, S46.	0.6	0

#	Article	IF	CITATIONS
253	Retinal photography: A diagnostic tool for small vessel disease of the brain?. Journal of the Neurological Sciences, 2009, 283, 273.	0.6	O
254	Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1125-1129.	1.9	86
255	Migraine and olcegepant – Authors' reply. Lancet, The, 2009, 373, 1003-1004.	13.7	0
256	The Lancet and advertorials. Lancet, The, 2009, 373, 1004-1005.	13.7	1
257	Neuroimaging in trigeminal autonomic cephalgias: when, how, and of what?. Current Opinion in Neurology, 2009, 22, 247-253.	3.6	67
258	Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. Journal of Clinical Investigation, 2009, 119, 99-109.	8.2	215
259	Reduced ACh release at neuromuscular synapses of heterozygous <i>leaner</i> Ca _v 2.1â€mutant mice. Synapse, 2008, 62, 337-344.	1.2	14
260	Enhanced circadian phase resetting in R192Q Ca _v 2.1 calcium channel migraine mice. Annals of Neurology, 2008, 64, 315-324.	5.3	33
261	Hypoxia-Induced Acute Mountain Sickness is Associated with Intracellular Cerebral Edema: A 3 T Magnetic Resonance Imaging Study. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 198-206.	4.3	86
262	Migraine Genetics: A Fascinating Journey Towards Improved Migraine Therapy. Headache, 2008, 48, 697-700.	3.9	14
263	Attack Frequency and Disease Duration as Indicators for Brain Damage in Migraine. Headache, 2008, 48, 1044-1055.	3.9	198
264	A Gene for a New Monogenic Neurovascular Migraine Syndrome: A Next Step in Unravelling Molecular Pathways for Migraine?. Cephalalgia, 2008, 28, 471-473.	3.9	3
265	<i>CACNA1A</i> Mutation Linking Hemiplegic Migraine and Alternating Hemiplegia of Childhood. Cephalalgia, 2008, 28, 887-891.	3.9	53
266	<i>CACNA1A </i> R1347Q: a frequent recurrent mutation in hemiplegic migraine. Clinical Genetics, 2008, 74, 481-485.	2.0	20
267	Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2. Neurobiology of Disease, 2008, 32, 10-15.	4.4	24
268	Frontal lobe structure and executive function in migraine patients. Neuroscience Letters, 2008, 440, 92-96.	2.1	127
269	Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet, The, 2008, 372, 2115-2123.	13.7	486
270	Migraine headache is not associated with cerebral or meningeal vasodilatationâ€"a 3T magnetic resonance angiography study. Brain, 2008, 131, 2192-2200.	7.6	212

#	Article	IF	CITATIONS
271	Divergent sodium channel defects in familial hemiplegic migraine. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9799-9804.	7.1	97
272	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: Progression of MR Abnormalities in Prospective 7-year Follow-up Study. Radiology, 2008, 249, 964-971.	7.3	38
273	Chapter 3 Familial Hemiplegic Migraine. Advances in Genetics, 2008, 63, 57-83.	1.8	30
274	A high-density association screen of 155 ion transport genes for involvement with common migraine. Human Molecular Genetics, 2008, 17, 3318-3331.	2.9	90
275	Migraine and epilepsy: genetically linked?. Expert Review of Neurotherapeutics, 2008, 8, 1307-1311.	2.8	7
276	Genetics of migraine: an update with special attention to genetic comorbidity. Current Opinion in Neurology, 2008, 21, 288-293.	3.6	24
277	A review of the genetic relation between migraine and epilepsy. Cephalalgia, 2008, 28, 105-13.	3.9	49
278	Lacunar Infarcts Are the Main Correlate With Cognitive Dysfunction in CADASIL. Stroke, 2007, 38, 923-928.	2.0	104
279	Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine. Neurology, 2007, 69, 2170-2176.	1.1	163
280	Genetic Models of Migraine. Archives of Neurology, 2007, 64, 643.	4.5	60
281	Trigeminal Autonomic Cephalgias Due to Structural Lesions. Archives of Neurology, 2007, 64, 25.	4.5	148
282	Epilepsy in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Cerebrovascular Diseases, 2007, 24, 316-317.	1.7	12
283	Migraine: gene mutations and functional consequences. Current Opinion in Neurology, 2007, 20, 299-305.	3.6	112
284	Characterization of acetylcholine release and the compensatory contribution of non-Cav2.1 channels at motor nerve terminals of leaner Cav2.1-mutant mice. Neuroscience, 2007, 144, 1278-1287.	2.3	25
285	The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Human Mutation, 2007, 28, 522-522.	2.5	89
286	<i>T</i> ₁ relaxation in in vivo mouse brain at ultraâ€high field. Magnetic Resonance in Medicine, 2007, 58, 390-395.	3.0	32
287	C-terminal truncations in human $3\hat{a}\in^2$ - $5\hat{a}\in^2$ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nature Genetics, 2007, 39, 1068-1070.	21.4	366
288	First case of compound heterozygosity in Na,K-ATPase gene ATP1A2 in familial hemiplegic migraine. European Journal of Human Genetics, 2007, 15, 884-888.	2.8	20

#	Article	IF	Citations
289	Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacnala-mutant mouserolling Nagoya. European Journal of Neuroscience, 2007, 25, 2009-2020.	2.6	50
290	John Edmeads Celebration of a Life (April 15, 1936?November 16, 2006). Headache, 2007, 47, 160-168.	3.9	1
291	The Phe-124-Cys and A-161T Variants of the Human 5-HT1BReceptor Gene Are Not Major Determinants of the Clinical Response to Sumatriptan. Headache, 2007, 47, 711-716.	3.9	15
292	Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database. Headache, 2007, 48, 070629211050002-???.	3.9	30
293	Migraine in The Elderly: A Review. Cephalalgia, 2007, 27, 97-106.	3.9	72
294	Typical Cluster Headache Caused by Granulomatous Pituitary Involvement. Cephalalgia, 2007, 27, 173-176.	3.9	14
295	Intractable Headache Criteria: Reply. Cephalalgia, 2007, 27, 859-859.	3.9	0
296	Redundancy of Cav2.1 channel accessory subunits in transmitter release at the mouse neuromuscular junction. Brain Research, 2007, 1143, 92-101.	2.2	12
297	Is stress a trigger factor for migraine?. Psychoneuroendocrinology, 2007, 32, 532-538.	2.7	34
298	Recurrent ATP1A2 mutations in Portuguese families with familial hemiplegic migraine. Journal of Human Genetics, 2007, 52, 990-998.	2.3	15
299	Migraine as a Cerebral Ionopathy with Abnormal Central Sensory Processing**Some portions of the pathophysiology have appeared fully referenced [1], 2007,, 333-348.		5
300	Migraine as a Cerebral Ionopathy with Impaired Central Sensory Processing. , 2007, , 439-461.		11
301	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Clinical and Experimental Hypertension, 2006, 28, 271-277.	1.3	18
302	Compensatory Contribution of Cav2.3 Channels to Acetylcholine Release at the Neuromuscular Junction of Tottering Mice. Journal of Neurophysiology, 2006, 95, 2698-2704.	1.8	25
303	Treating Migraine Attacks ASAP: Concept and Methodological Issues. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 53-61.	0.0	0
304	Evaluating the IHS Criteria for Cluster Headache – a Comparison between Patients Meeting all Criteria and Patients Failing One Criterion. Cephalalgia, 2006, 26, 241-245.	3.9	30
305	Cardiovascular Autonomic Function Tests in Cluster Headache. Cephalalgia, 2006, 26, 329-331.	3.9	13
306	Normobaric Hypoxia and Nitroglycerin as Trigger Factors for Migraine. Cephalalgia, 2006, 26, 816-819.	3.9	62

#	Article	IF	CITATIONS
307	Towards a Definition of Intractable Headache for Use in Clinical Practice and Trials. Cephalalgia, 2006, 26, 1168-1170.	3.9	185
308	The Prevalence of Premonitory Symptoms in Migraine: A Questionnaire Study in 461 Patients. Cephalalgia, 2006, 26, 1209-1213.	3.9	158
309	Genetic Biomarkers for Migraine. Headache, 2006, 46, 1059-1068.	3.9	39
310	Hemiplegic and Basilar-type Migraine: Current and Future Treatment. Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2006, 3, 97-100.	0.7	2
311	Two de novo mutations in the Na,K-ATPase gene ATP1A2 associated with pure familial hemiplegic migraine. European Journal of Human Genetics, 2006, 14, 555-560.	2.8	56
312	Conditional inactivation of the Cacna 1a gene in transgenic mice. Genesis, 2006, 44, 589-594.	1.6	30
313	Migraine and MTHFR C677T genotype in a populationâ€based sample. Annals of Neurology, 2006, 59, 372-375.	5. 3	193
314	Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation. Annals of Neurology, 2006, 59, 310-314.	5.3	72
315	Alternating Hemiplegia of Childhood: No Mutations in the Glutamate Transporter EAAT1. Neuropediatrics, 2006, 37, 302-304.	0.6	15
316	Cluster headache in women: relation with menstruation, use of oral contraceptives, pregnancy, and menopause. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 690-692.	1.9	46
317	Syncope in migraine. Neurology, 2006, 66, 1034-1037.	1.1	118
318	Brain Stem and Cerebellar Hyperintense Lesions in Migraine. Stroke, 2006, 37, 1109-1112.	2.0	141
319	The 3p21.1-p21.3 Hereditary Vascular Retinopathy Locus Increases the Risk for Raynaud's Phenomenon and Migraine. Cephalalgia, 2005, 25, 1168-1172.	3.9	24
320	Chronic Daily Headache in Children and Adolescents. Headache, 2005, 45, 678-683.	3.9	37
321	Migraine as a Risk Factor for White Matter Lesions, Silent Infarctions, and Ischemic Stroke: The Evidence for a Link. Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2005, 2, 62-70.	0.7	1
322	The use of multiattribute decision models in evaluating triptan treatment options in migraine. Journal of Neurology, 2005, 252, 1026-1032.	3.6	22
323	Chronic cluster headache: a review. Journal of Headache and Pain, 2005, 6, 3-9.	6.0	21
324	Verapamil induced gingival enlargement in cluster headache. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 124-127.	1.9	33

#	Article	IF	Citations
325	Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain, 2005, 128, 2068-2077.	7.6	328
326	Migraine: new treatment options from molecular biology. Expert Review of Neurotherapeutics, 2005, 5, 653-661.	2.8	3
327	How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Current Medical Research and Opinion, 2005, 21, 413-424.	1.9	32
328	Should We Advise Patients to Treat Migraine Attacks Early: Methodologic Issues. European Neurology, 2005, 53, 17-21.	1.4	17
329	Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet, The, 2005, 366, 371-377.	13.7	760
330	Cardiovascular risk factors and migraine. Neurology, 2005, 64, 614-620.	1.1	426
331	Gene dosage-dependent transmitter release changes at neuromuscular synapses of Cacna1a R192Q knockin mice are non-progressive and do not lead to morphological changes or muscle weakness. Neuroscience, 2005, 135, 81-95.	2.3	45
332	MRI findings in migraine. Revue Neurologique, 2005, 161, 661-665.	1.5	36
333	Migraine as a Risk Factor for Subclinical Brain Lesions. JAMA - Journal of the American Medical Association, 2004, 291, 427.	7.4	845
334	Alternating Hemiplegia of Childhood: No Mutations in the Second Familial Hemiplegic Migraine GeneATP1A2. Neuropediatrics, 2004, 35, 293-296.	0.6	30
335	A breathtaking headache. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 509-509.	1.9	2
336	Migraine as a Risk Factor for Subclinical Brain Lesionsâ€"Reply. JAMA - Journal of the American Medical Association, 2004, 291, 2072.	7.4	2
337	Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new <i>CACNA1A</i> mutation. Neurology, 2004, 63, 1136-1137.	1.1	102
338	Single-fiber EMG in familial hemiplegic migraine. Neurology, 2004, 63, 1942-1943.	1.1	28
339	A Patient with Long-Lasting Attacks of Bilateral â€~Blepharospasm', Photophobia, Lacrimation and Rhinorrhoea. Cephalalgia, 2004, 24, 143-146.	3.9	5
340	Ophthalmoplegic Migraine: Migrainous or Inflammatory?. Cephalalgia, 2004, 24, 312-315.	3.9	44
341	Reply: Impairment of Trigeminal Sensory Pathways in Cluster Headache. Cephalalgia, 2004, 24, 910-911.	3.9	1
342	Should We Advise Patients to Treat Migraine Attacks Early?. Cephalalgia, 2004, 24, 915-927.	3.9	31

#	Article	IF	CITATIONS
343	TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurologica Scandinavica, 2004, 110, 137-143.	2.1	23
344	Toward a molecular genetic classification of familial hemiplegic migraine. Current Pain and Headache Reports, 2004, 8, 238-243.	2.9	10
345	Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project. Current Pain and Headache Reports, 2004, 8, 435-442.	2.9	15
346	Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR project). Clinical Therapeutics, 2004, 26, 1533-1545.	2.5	19
347	A Cacnala Knockin Migraine Mouse Model with Increased Susceptibility to Cortical Spreading Depression. Neuron, 2004, 41, 701-710.	8.1	595
348	Recent findings in headache genetics. Current Opinion in Neurology, 2004, 17, 283-288.	3.6	52
349	Transmitter Release Deficits at the Neuromuscular Synapse of Mice with Mutations in the Cav2.1 ($\hat{l}\pm1A$) Subunit of the P/Q-Type Ca2+Channel. Annals of the New York Academy of Sciences, 2003, 998, 29-32.	3 . 8	7
350	Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathologica, 2003, 106, 107-111.	7.7	60
351	Novel mutations in the Na+, K+-ATPase pump geneATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Annals of Neurology, 2003, 54, 360-366.	5 . 3	330
352	Letters to the Editor. Headache, 2003, 43, 814-823.	3.9	2
353	Sunct Syndrome Resolving After Contralateral Hemispheric Ischaemic Stroke. Cephalalgia, 2003, 23, 235-237.	3.9	12
354	Impairment of Trigeminal Sensory Pathways in Cluster Headache. Cephalalgia, 2003, 23, 414-419.	3.9	28
355	Authors' Reply: Abdominal Migraine. Cephalalgia, 2003, 23, 242-242.	3.9	O
356	Cerebral Hemodynamics and White Matter Hyperintensities in CADASIL. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 599-604.	4.3	70
357	Genetic factors in cluster headache. Expert Review of Neurotherapeutics, 2003, 3, 301-306.	2.8	9
358	Intranasal sumatriptan in cluster headache. Neurology, 2003, 60, 630-633.	1.1	168
359	Trigeminal autonomic cephalalgia-tic-like syndrome associated with a pontine tumour in a one year old girl. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 391-392.	1.9	7
360	Features involved in the diagnostic delay of cluster headache. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1123-1125.	1.9	121

#	Article	IF	CITATIONS
361	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: MR Imaging Findings at Different Ages—3rd–6th Decades. Radiology, 2003, 229, 683-690.	7.3	165
362	Expanding the Phenotypic Spectrum of the CACNA1A Gene T666M Mutation. Archives of Neurology, 2003, 60, 684.	4.5	84
363	Myocardial Infarction in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Medicine (United States), 2003, 82, 251-256.	1.0	51
364	Incipient CADASIL. Archives of Neurology, 2003, 60, 707.	4.5	38
365	Voxel-Based Morphometry in Hypocretin-Deficient Narcolepsy. Sleep, 2003, , .	1.1	19
366	Current perspectives on effective migraine treatments: are small clinical differences important for patients?. Drugs of Today, 2003, 39 Suppl D, 37-41.	1.1	0
367	Mutation Analysis of the CACNA1A Calcium Channel Subunit Gene in 27 Patients With Sporadic Hemiplegic Migraine. Archives of Neurology, 2002, 59, 1016.	4.5	82
368	Subcortical Lacunar Lesions: An MR Imaging Finding in Patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Radiology, 2002, 224, 791-796.	7.3	97
369	Calcium channel mutations and migraine. Current Opinion in Neurology, 2002, 15, 311-316.	3.6	29
370	Migraine â€" Current Understanding and Treatment. New England Journal of Medicine, 2002, 346, 257-270.	27.0	1,692
371	The hypothalamus in episodic brain disorders. Lancet Neurology, The, 2002, 1, 437-444.	10.2	59
372	Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Annals of Neurology, 2002, 51, 369-372.	5.3	108
373	Episodic ataxia type 2. Journal of Neurology, 2002, 249, 1515-1519.	3.6	34
374	Tripstar: A Comprehensive Patient-Based Approach to Compare Triptans. Headache, 2002, 42, 18-25.	3.9	8
375	Reproducibility and Feasibility of Neurophysiological Assessment of the Sensory Trigeminal System for Future Application To Paroxysmal Headaches. Cephalalgia, 2002, 22, 474-481.	3.9	7
376	Triptans (Serotonin, 5-HT _{1B/1D} Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials. Cephalalgia, 2002, 22, 633-658.	3.9	554
377	Familial Cyclic Vomiting Syndrome. Cephalalgia, 2002, 22, 552-554.	3.9	27
378	George W. Bruyn, Born Delft, 14 December 1928, Died La Salvetat, 23 June 2002. Cephalalgia, 2002, 22, 767-768.	3.9	1

#	Article	IF	CITATIONS
379	The genetics of migraine: implication for treatment approaches. , 2002, , 111-127.		4
380	Hereditary Vascular Retinopathy, Cerebroretinal Vasculopathy, and Hereditary Endotheliopathy with Retinopathy, Nephropathy, and Stroke Map to a Single Locus on Chromosome 3p21.1-p21.3. American Journal of Human Genetics, 2001, 69, 447-453.	6.2	127
381	Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet, The, 2001, 358, 1230-1234.	13.7	163
382	Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, The, 2001, 358, 1668-1675.	13.7	927
383	Meta-Analysis of Rizatriptan Efficacy in Randomized Controlled Clinical Trials. Cephalalgia, 2001, 21, 129-136.	3.9	51
384	No Involvement of the Calcium Channel Gene (CACNA1A) in a Family with Cluster Headache. Cephalalgia, 2001, 21, 959-962.	3.9	42
385	The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Cephalalgia, 2001, 21, 672-679.	3.9	21
386	Editorial Commentary. Cephalalgia, 2001, 21, 711-711.	3.9	4
387	Delayed cerebral edema and fatal coma after minor head trauma: Role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Annals of Neurology, 2001, 49, 753-760.	5.3	318
388	The impact of pharmacogenetics for migraine. European Journal of Pharmacology, 2001, 413, 1-10.	3.5	23
389	Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology, 2001, 57, 1377-1383.	1.1	53
390	Involvement of the <i>CACNA1A</i> gene containing region on 19p13 in migraine with and without aura. Neurology, 2001, 56, 1028-1032.	1.1	130
391	Sumatriptan by Injection. Cephalalgia, 2001, 21, 6-8.	3.9	5
392	Cerebral microbleeds in CADASIL. Neurology, 2001, 57, 1066-1070.	1.1	209
393	Within-patient consistency of response of rizatriptan for treating migraine. Neurology, 2000, 55, 1511-1516.	1.1	41
394	Mahler's Migraine. Cephalalgia, 2000, 20, 254-254.	3.9	17
395	The Influence of Ergotamine Abuse on Psychological and Cognitive Functioning. Cephalalgia, 2000, 20, 462-469.	3.9	13
396	Guidelines for Controlled Trials of Drugs in Migraine: Second Edition. Cephalalgia, 2000, 20, 765-786.	3.9	615

#	Article	IF	CITATIONS
397	Rizatriptan: A New Milestone in Migraine Treatment. Introduction. Cephalalgia, 2000, 20, 1-1.	3.9	5
398	Alternating Hemiplegia of Childhood: No Mutations in the Familial Hemiplegic Migraine CACNA1A Gene. Cephalalgia, 2000, 20, 696-700.	3.9	32
399	Migraine Aura, Illusory Vertical Splitting, and Picasso. Cephalalgia, 2000, 20, 686-686.	3.9	11
400	CACNA1A gene mutations in familial hemiplegic migraine. Journal of Headache and Pain, 2000, 1, S121-S128.	6.0	0
401	Abnormal transmitter release at neuromuscular junctions of mice carrying the tottering alpha1A Ca2+ channel mutation. Brain, 2000, 123, 463-471.	7.6	81
402	Acetazolamide treatment for migraine aura status. Neurology, 2000, 55, 1588-1589.	1.1	65
403	Eletriptan in acute migraine. Neurology, 2000, 54, 156-156.	1.1	187
404	Ergotamine in the acute treatment of migraine: A review and European consensus. Brain, 2000, 123, 9-18.	7.6	329
405	The impact of migraine on quality of life in the general population. Neurology, 2000, 55, 624-629.	1.1	300
406	No acute antimigraine efficacy of CPâ€122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, doubleâ€blind, placeboâ€controlled clinical trials. Annals of Neurology, 2000, 47, 238-241.	5.3	3
407	Search for mitochondrial DNA mutations in migraine subgroups. Cephalalgia, 1999, 19, 20-22.	3.9	4
408	Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. British Journal of Clinical Pharmacology, 1999, 47, 285-290.	2.4	21
409	Human Isolated Coronary Artery Contraction To Sumatriptan: A Post Hoc Analysis. Cephalalgia, 1999, 19, 651-654.	3.9	21
410	Repeatability of the Intensity Dependence of Cortical Auditory Evoked Potentials in the Assessment of Cortical Information Processing. Cephalalgia, 1999, 19, 873-879.	3.9	23
411	Auditory Evoked Potentials in the Assessment of Central Nervous System Effects of Antimigraine Drugs. Cephalalgia, 1999, 19, 880-885.	3.9	25
412	Bovine isolated middle cerebral artery contractions to antimigraine drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360, 591-596.	3.0	14
413	Nerve conduction sensitivity in diabetic neuropathy. , 1999, 22, 140-140.		2
414	Genetics of primary headaches. Current Opinion in Neurology, 1999, 12, 249-254.	3.6	18

#	Article	IF	Citations
415	Diagnostic Notch3 sequence analysis in CADASIL: Three new mutations in Dutch patients. Neurology, 1999, 52, 1913-1913.	1.1	72
416	The prevalence and characteristics of migraine in a population-based cohort. Neurology, 1999, 53, 537-537.	1.1	488
417	Migraine, ataxia and epilepsy: a challenging spectrum of genetically determined calcium channelopathies. European Journal of Human Genetics, 1998, 6, 297-307.	2.8	81
418	Chromosomal localization of the 5-HT1F receptor gene: No evidence for involvement in response to sumatriptan in migraine patients. American Journal of Medical Genetics Part A, 1998, 77, 415-420.	2.4	28
419	The Transition G To A at Position 20210 in the 3'-Untranslated Region of the Prothrombin Gene is Not Associated with Migrainous Infarction. Cephalalgia, 1998, 18, 229-230.	3.9	7
420	5-HT1B Receptor Polymorphism and Clinical Response to Sumatriptan. Headache, 1998, 38, 288-291.	3.9	60
421	P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy. Trends in Pharmacological Sciences, 1998, 19, 121-127.	8.7	58
422	Migraine. Lancet, The, 1998, 351, 1043-1051.	13.7	449
423	Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs. Circulation, 1998, 98, 25-30.	1.6	314
424	The Economic Burden of Migraine to Society. Pharmacoeconomics, 1998, 13, 667-676.	3.3	156
425	Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Neurology, 1998, 50, 1105-1111.	1.1	132
426	Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain, 1998, 121, 303-316.	7.6	107
427	Prothrombotic mutations and ischaemic stroke at a young age in two sisters. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 958-959.	1.9	0
428	Genetics and pathology of voltage-gated Ca2+ channels. Histology and Histopathology, 1998, 13, 827-36.	0.7	3
429	Interictal cortical excitability to magnetic stimulation in familial hemiplegic migraine. Neurology, 1997, 48, 1462-1464.	1.1	63
430	311C90: Increasing the options for therapy with effective acute antimigraine 5HT $<$ sub $>$ 1B/1D $<$ /sub $>$ receptor agonists. Neurology, 1997, 48, S21-4.	1.1	46
431	The quest for migraine genes. Current Opinion in Neurology, 1997, 10, 221-225.	3.6	6
432	GENETICS OF MIGRAINE. Neurologic Clinics, 1997, 15, 43-60.	1.8	50

#	Article	IF	Citations
433	Partial Cosegregation of Familial Hemiplegic Migraine and a Benign Familial Infantile Epileptic Syndrome. Epilepsia, 1997, 38, 915-921.	5.1	50
434	Involvement of a Ca 2+ Channel Gene in Familial Hemiplegic Migraine and Migraine With and Without Aura. Headache, 1997, 37, 479-485.	3.9	40
435	The Factor V Leiden Mutation (R506Q) is not a Major Risk Factor for Migrainous Cerebral Infarction. Cephalalgia, 1997, 17, 605-607.	3.9	19
436	Double-Blind, Placebo-Controlled, Dose-Finding Study of Rizatriptan (MK-462) in the Acute Treatment of Migraine. Cephalalgia, 1997, 17, 647-651.	3.9	74
437	Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. Journal of the Neurological Sciences, 1996, 139, 106-110.	0.6	100
438	Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. British Journal of Pharmacology, 1996, 119, 855-862.	5.4	41
439	Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain, 1996, 67, 375-378.	4.2	110
440	Familial Hemiplegic Migraine and Episodic Ataxia Type-2 Are Caused by Mutations in the Ca2+ Channel Gene CACNL1A4. Cell, 1996, 87, 543-552.	28.9	2,287
441	The Clinical Effectiveness of 311C90 in the Acute Treatment of Migraine. European Neurology, 1996, 36, 4-7.	1.4	17
442	Monthly Update: Central & Deripheral Nervous Systems: Pharmacology of antimigraine 5-HT _{1D} receptor agonists. Expert Opinion on Investigational Drugs, 1996, 5, 581-593.	4.1	17
443	Emerging Preclinical and Clinical Profile of 311C90: A Poster Review and Discussion. European Neurology, 1996, 36, 19-23.	1.4	4
444	311C90, A new central and peripherally acting 5-HT _{1D} receptor agonist in the acute oral treatment of migraine. Neurology, 1996, 46, 522-526.	1.1	81
445	Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response*. Clinical Pharmacology and Therapeutics, 1996, 60, 452-460.	4.7	38
446	Sumatriptan - Nonresponders: A Survey in 366 Migraine Patients. Headache, 1996, 36, 471-475.	3.9	44
447	Familial Hemiplegic Migraine: A Clinical Comparison of Families Linked and Unlinked to Chromosome 19. Cephalalgia, 1996, 16, 153-155.	3.9	70
448	Risk Factors for Headache Recurrence After Sumatriptan: A Study in 366 Migraine Patients. Cephalalgia, 1996, 16, 264-269.	3.9	99
449	Chest Symptoms after Sumatriptan. Cephalalgia, 1996, 16, 554-559.	3.9	87
450	Rizatriptan vs Sumatriptan in the Acute Treatment of Migraine. Archives of Neurology, 1996, 53, 1132.	4.5	157

#	Article	IF	Citations
451	Sumatriptan in clinical practice. Neurology, 1996, 47, 46-51.	1.1	120
452	Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. Journal of the Neurological Sciences, 1996, 139, 106-110.	0.6	48
453	Acute treatment of migraine attacks. Current Opinion in Neurology, 1995, 8, 237-242.	3.6	14
454	5â€HT ₁ receptors in migraine pathophysiology and treatment. European Journal of Neurology, 1995, 2, 5-21.	3.3	76
455	Is Familial Hemiplegic Migraine a Hereditary form of Basilar Migraine?. Cephalalgia, 1995, 15, 477-481.	3.9	66
456	Familial hemiplegic migraine locus on $19p13$ is involved in the common forms of migraine with and without aura. Human Genetics, 1995 , 96 , 604 - 608 .	3.8	167
457	Cerebral Blood Flow During Migraine Attacks Without Aura and Effect of Sumatriptan. Archives of Neurology, 1995, 52, 135-139.	4.5	62
458	Assessment of Peripheral Vascular Effects of Antimigraine Drugs in Humans. Cephalalgia, 1995, 15, 288-291.	3.9	18
459	Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology, 1995, 45, 1505-1509.	1.1	34
460	Dihydroergotamine nasal spray. Neurology, 1995, 45, 397.	1.1	2
461	A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13. Clinical Neurology and Neurosurgery, 1995, 97, 307-313.	1.4	33
462	Intracellular and Plasma Magnesium in Familial Hemiplegic Migraine and Migraine With and Without Aura. Cephalalgia, 1994, 14, 29-32.	3.9	19
463	Oral Sumatriptan: Effect of a Second Dose, and Incidence and Treatment of Headache Recurrences. Cephalalgia, 1994, 14, 330-338.	3.9	109
464	Genetic Heterogeneity of Familial Hemiplegic Migraine. Genomics, 1994, 22, 21-26.	2.9	136
465	Familial hemiplegic migraine in the Netherlands. Clinical Neurology and Neurosurgery, 1994, 96, 244-249.	1.4	47
466	Genetic biomarkers. Journal of Cellular Biochemistry, 1993, 53, 205-205.	2.6	0
467	On Serotonin and Migraine: A Clinical and Pharmacological Review. Cephalalgia, 1993, 13, 151-165.	3.9	206
468	Dopamine D2–Receptor Imaging With 123I-lodobenzamide SPECT in Migraine Patients Abusing Ergotamine: Does Ergotamine Cross The Blood Brain Barrier?. Cephalalgia, 1993, 13, 325-329.	3.9	12

#	Article	IF	Citations
469	Transient Resolution of Headache in Giant Cell Temporal Arteritis After Sumatriptan. Cephalalgia, 1993, 13, 426-426.	3.9	5
470	Clinical and experimental effects of sumatriptan in humans. Trends in Pharmacological Sciences, 1993, 14, 129-133.	8.7	111
471	Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine Stroke, 1993, 24, 1335-1338.	2.0	49
472	Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia Stroke, 1993, 24, 1655-1663.	2.0	30
473	Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study. Sleep, 1993, 16, 216-220.	1.1	184
474	Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology, 1992, 42, 1522-1522.	1.1	99
475	Clinical effects and mechanism of action of sumatriptan in migraine. Clinical Neurology and Neurosurgery, 1992, 94, 73-77.	1.4	30
476	Effects of tertatolol, a \hat{I}^2 -adrenoceptor antagonist with agonist affinity at 5-HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. European Journal of Pharmacology, 1992, 220, 79-86.	3.5	10
477	Blood Flow Velocities in the Vertebrobasilar System During Migraine Attacks a Transcranial Doppler Study. Cephalalgia, 1992, 12, 29-32.	3.9	21
478	From Serotonin Receptor Classification to the Antimigraine Drug Sumatriptan. Cephalalgia, 1992, 12, 187-196.	3.9	45
479	Treatment of Migraine Attacks with Subcutaneous Sumatriptan: First Placebo-Controlled Study. Cephalalgia, 1992, 12, 308-313.	3.9	34
480	Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. Pain, 1991, 45, 283-291.	4.2	25
481	Ergot Alkaloids Reduce Cranial Arteriovenous Shunting In Pigs: No Major Role for 5-Ht ₁ -Like Receptors. Cephalalgia, 1991, 11, 203-204.	3.9	2
482	Effect of Sumatriptan on Cerebral Bloodflow During and Outside Migraine Attacks: A Tc-99M Hmpao Spect and Transcranial Doppler Study Cephalalgia, 1991, 11, 205-205.	3.9	0
483	5-HT3 receptor antagonists and migraine therapy. Journal of Neurology, 1991, 238, S53-S56.	3.6	25
484	Plasma Interleukin-1, Tumour Necrosis Factor and Hypothalamic-Pituitary-Adrenal Axis Responses During Migraine Attacks. Cephalalgia, 1991, 11, 65-67.	3.9	44
485	Blood Flow Velocity Changes in Migraine Attacks-A Transcranial Doppler Study. Cephalalgia, 1991, 11, 103-107.	3.9	51
486	Treatment of Migraine Attacks with Sumatriptan. New England Journal of Medicine, 1991, 325, 316-321.	27.0	527

#	Article	IF	Citations
487	Methionine-Enkephalin in Migraine and Tension Headache. Differences Between Classic Migraine, Common Migraine and Tension Headache, and Changes During Attacks Headache, 1990, 30, 160-164.	3.9	13
488	Neuroexcitatory plasma amino acids are elevated in migraine. Neurology, 1990, 40, 1582-1582.	1.1	138
489	Vascular Effects of Serotonin in Migraine Patients. Cephalalgia, 1989, 9, 86-87.	3.9	0
490	Characterization of virus infected cell cultures by pyrolysis/direct chemical ionization mass spectrometry. Biomedical & Environmental Mass Spectrometry, 1989, 18, 757-760.	1.6	7
491	5-HT1-like receptor agonists and the pathophysiology of migraine. Trends in Pharmacological Sciences, 1989, 10, 200-204.	8.7	129
492	Release of platelet Met-enkephalin, but not serotonin, in migraine. Journal of the Neurological Sciences, 1989, 93, 51-60.	0.6	19
493	Serotonin metabolism in migraine. Neurology, 1989, 39, 1239-1239.	1.1	232
494	Intermittent pyramidal claudication as presenting and sole symptom in multiple sclerosis Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 147-148.	1.9	4
495	Relief of common migraine by exercise Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1011-1011.	1.9	0
496	Bromocriptineâ€induced trigeminal patient with a neuralgia attacks in a pituitary tumor. Neurology, 1988, 38, 1482-1482.	1.1	43
497	PARKINSONISM, TARDIVE DYSKINESIA, AKATHISIA, AND DEPRESSION INDUCED BY FLUNARIZINE. Lancet, The, 1986, 328, 292.	13.7	36
498	Chorea and Migraine: "Hemicrania Choreatica�. Cephalalgia, 1984, 4, 119-124.	3.9	4
499	A Migrainous Syndrome with Pleocytosis. Neurology, 1983, 33, 813-813.	1.1	8
500	Treating migraine attacks ASAP: concept and methodological issues., 0,, 53-62.		0